Abaloparatide

Abaloparatide (BA058) is a synthetic 34-amino acid peptide analog of human parathyroid hormone-related protein (PTHrP). It was developed as a selective activator of the parathyroid hormone 1 receptor (PTH1R) with a preferential binding to the RG receptor conformation, which is associated with transient cAMP signaling. Abaloparatide was approved by the FDA in 2017 under the brand name Tymlos for the treatment of postmenopausal osteoporosis in patients at high risk of fracture. Unlike teriparatide (PTH 1-34), abaloparatide was engineered to favor anabolic bone signaling over resorptive pathways by preferentially stabilizing the RG conformation of PTH1R. The peptide contains an alpha-aminoisobutyric acid (Aib) substitution at position 29 that confers enhanced receptor selectivity and metabolic stability compared to native PTHrP.

Abaloparatide has been investigated for its selective activation of the PTH1R receptor through preferential binding to the RG (G-protein-dependent) conformation rather than the R0 (G-protein-independent) conformation. Researchers observed that this binding preference results in transient, rather than sustained, cAMP signaling in osteoblasts. Studies suggest that transient PTH1R activation favors anabolic bone formation by stimulating osteoblast proliferation and differentiation while minimizing the osteoclast-activating effects associated with prolonged receptor stimulation. In preclinical models, researchers observed that abaloparatide treatment was associated with increased bone mineral density, trabecular connectivity, and cortical thickness. The Aib substitution at position 29 reduces receptor internalization kinetics, contributing to the transient signaling profile. Additionally, abaloparatide has been shown to activate Wnt/beta-catenin signaling in osteoblast lineage cells, a key pathway in bone formation.

Fracture Risk Reduction

Miller et al. (2016) conducted the ACTIVE Phase 3 trial investigating abaloparatide in postmenopausal women with osteoporosis. Researchers observed significant reductions in new vertebral and nonvertebral fracture incidence compared to placebo over 18 months, leading to FDA approval [1].

Bone Microarchitecture

Varela et al. (2017) used micro-CT analysis to investigate the effects of abaloparatide on trabecular and cortical bone in ovariectomized rat models. Researchers observed improvements in trabecular number, thickness, and connectivity density compared to vehicle-treated controls [2].

Receptor Selectivity

Hattersley et al. (2016) characterized abaloparatide’s binding pharmacology at PTH1R, demonstrating preferential binding to the RG conformation. This work provided the mechanistic basis for the peptide’s favorable ratio of bone formation to bone resorption observed in preclinical and clinical studies [3].